O
`62) United States Patent
`(10) Patent No.:
`US 7,083,957 32
`
`Rosenblum et al.
`(45) Date of Patent:
`Aug. 1, 2006
`
`
`
`USOO708395732
`
`5.710.195 A
`5.837.491 A
`6.084.073 A
`
`611998 Hudziak e1 :1].
`1111998 Better at al.
`Tut-"2000 Piatak..11’.
`
`......... 424.:‘13UJ
`.. 435-69.]
`
`5301370
`
`gflgfigifi 31
`.
`.
`6.306.626 131
`Rli3'1'.462 E
`6.599.505 Bl
`6.669.938 BI
`6.350.329 131
`2003411173163 Al
`200330086919 .41
`2003911134302 Al
`200310186384 A1
`20114100119477 Al
`
`3333? fiasruhft a]. "EH-W" 2:313;
`osen urn el
`.
`..
`.-'3
`.
`10.12001 Roscnblilm et a].
`433170.21
`[212001 Rosenblilm ct al.
`........ 5301370
`7.12003 Rosenhlnm .............. 424-"134J
`1212003 Rosenbluin 61 a].
`424.-'l83.|
`6.12004 Rosenblilm ct al.
`5301391.?
`412003 Fernandez ct .11.
`435-69.]
`512003 Rosenbluin 61 a].
`4124:9463
`”112003 Fernandez et al.
`435.16
`1012003 Barth Ct 31.
`.. 4351695
`
`11"2004 Fernandez et a1.
`43516
`
`.
`
`200450013691 A]
`
`11"2004 Rosenblnin .............. 424.2341
`
`AU
`AU
`AU
`AU
`AU
`L-‘p
`.E:
`EP
`EP
`up
`EP
`EP
`LP
`
`FOREIGN PATENT DOCUMENTS
`329527.587
`41-1988
`38204718?
`611988
`A1301'FF88
`9-" 1988
`.-'\21725."88
`3.31989
`9130753189
`81’ 1989
`01133.55
`311934
`3:2’3‘32
`2:332
`0184369
`lI.-'l985
`0226418
`12-1986
`0222360
`5.5198?
`0256714
`211988
`0281020
`9.31988
`0305957
`331939
`(Continued)
`OTHER PUBLICATIONS
`
`.-
`
`Better et a1. 1994: .1. Biological Chemistry 269(13): 9644—
`9650*
`;
`.
`.
`'
`.
`.
`.
`.
`.
`.
`|,MS Microbiology Letters 146.91
`1
`321131.011 et a1. 1997,
`.
`.
`.
`.
`'
`Parakli ct al. 1995;Proecedings ofthe American Assoctation
`tor Cancer Research Annual Meeting 36:488. abstract
`t!
`2909*
`Sulirhicr 61 a1. 1991; J. Immunology 147(8): 2507—2513}
`11.8. Appl. No. 101676.725, filed Oct. 1. 2003. Roscnblum.
`USAPPLNQ 101926.731. filedAug_ 26. 2004‘ Rosenblum.
`
`_
`
`(Continued)
`
`Priiiraqit Examirwr—Karen Cochrane Carlson
`(74).4tr0rnc_1’. Agent. or [-'fmi Fulbright & Jaworski. I..I..1-’.
`
`(57)
`
`ABSTRACT
`
`invention concerns methods 01‘ reducing the
`The present
`.
`_
`.
`.
`.
`.
`.
`.
`.
`antigenictly 01a protcmaceous compound while maintaining
`the compounds biological aelivity. as well as proteiliaecous
`compositions with biological activity but reduced antigenic—
`ity. These methods and compositions have significant ben—
`elits to a subject in need of such compounds and composi-
`lions. Also included are modified toxin compounds that are
`truncated andfor possess reduce antigenicity. Such designer
`toxins have therapeutic. diagnostic. and preventative ben—
`efitt- particularly mamas... Methods of treating
`cancer using lhesc nnmunotoxnis are provuled.
`
`41 Claims. 11 Drawing Sheets
`
`IMMUNOGEN 2075, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`(54) MODIFIED PROTEINS, DESIGNER TDXINS,
`AND METHODS OF NIAKING THEREOF
`
`(75)
`
`Inventors: Michael G. Rosenhlum. Sugarlaiid. TX
`.
`.
`.
`‘
`..
`..
`E33; [“mm'w ('heung‘ ”0mm“ Ix
`1
`,
`.
`(73) “5'8““: 9935““? ”evfk'P'flem I"“’““““'"“t
`($5011 (-lly- NV (US)
`.
`_
`.
`_
`.
`Subject to any dlsclalmer. theleml 01 tins
`patent is extended or adjusted under 35
`11.S.C. 154-02011)! 781 days.
`
`_
`(”‘1 Notlce:
`
`(2]) Appl. Na: 1|);0745596
`
`(22]
`
`l-‘iled:
`
`Feb. 12, 2002
`
`(65)
`
`Prior Publication Data
`
`US 2003110176331 ‘41
`
`88]). 18. 2003
`
`Related [1.8. Application Data
`Provisional application No. 601268.402. filed on Feb.
`12» 2001-
`
`(2006.01)
`
`Int. Cl.
`CIZN 9/00
`4351183
`[1.5. CI.
`4351183
`Field of Classification Search
`See application file for complete search history.
`References Cited
`
`(60)
`
`(51)
`
`(52)
`(58)
`
`(56)
`
`11.5. PATIENT 1I)CUMI€N‘1‘S
`
`424.585
`4.51981 Sela Ct 81.
`.. 53013919
`ll-'l983 Jansen cl 3L
`
`.. 435.-'(8
`6:" 985 . hl
`21.1.
`
`.. 424:};5
`511986 :EanLiigneLt al.
`33937 Aggwal 6. 3L __
`424.535
`
`.. 424185
`611981r RodWell el al.
`3.. 435168
`61198? Mark et a].
`
`651988 Frankel et a].
`436:“548
`
`9-1988 Ferris el al.
`5301391.?
`1.319189 Monsigny et a1.
`514.58
`5.-"1989 Bilchsbaum etal.
`53013913
`9-"1989 Stevenset a1.
`424185.}!
`9.11989 Rubin e1 a1. ____
`5301413
`1211989 Lambert etal.
`.
`..... 5301390
`.. 424.-"85.1
`131990 Zimmerman
`111990 Stevens El 211.
`42485.2
`
`5303388
`131990 Greenfield ct a].
`.. 424.-"85.5
`6:"1990 Bell Ct
`:11.
`35369.6
`831990 I.:I.nd.ner el al.
`530.889
`[0.11990 Frankel
`AAAAAAA
`424185. 1
`10.1990 Shepard et al.
`_____ 530.391
`[3.51990 Jansen ct at.
`424.1355
`5.199] cumming
`424-"l.l
`5.-"1991 Epstein ct a].
`43532402?
`7:"1991 White ct .11.
`539-53873
`70992 HellSlnll" et 31-
`5315-1234
`[011994 (7.1me e‘ 31-
`
`31833 3:35.260}:2.";1'":::::-53.253{1%
`5:19.}? Rosenblum a it].
`530.3320
`2.51998
`lllldziak Ct 31.
`42451301
`411998 Bettcret a1.
`530132?
`
`
`
`
`
`
`__
`
`.
`
`
`
`4.263.229 A
`4.414.|48 A
`4.522.918
`4.59090“ 1:
`4‘550‘5-14 A
`4.671.958 A
`4.6??.Ufi4 A
`4.753.894 A
`4.771.128 A
`4.801.578 A
`4.831.122 A
`4.863.226 A
`4,870,163 A
`4.888.415 A
`4.894.225 A
`4,894.22? A
`4.894.443 A
`4.935.233 A
`4.946.728
`4.962. | 88
`4.963.354 A
`433.145? A
`5317371 A
`5.Ul9.368 A
`5.U32.521 A
`5- 1 34-015 A
`5359346 A
`212311233 :2
`5‘6“...)48 A
`5.720.954 A
`5.744.580 A
`
`AA
`
`IMMUNOGEN 2075, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`US 7,083,957 B2
`Page 2
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`EP
`GB
`GB
`JP
`JP
`JP
`W0
`W0
`W0
`W0
`Wt)
`W0
`W0
`W0
`W0
`W0
`W0
`Wt)
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`0336631
`03 502 30
`0396387II
`1564666
`2148299
`86121
`62209098
`190200
`W0 85-"009i4
`W0 86.05098
`W0 86:02945
`W0 81-10056
`W0 88-09343
`W0 88-09344
`W0 8906692
`W0 90:"00405
`W0 91i160?1
`W0 94;"26910
`W0 97322364
`W0 97:"46259
`W0 99.9'40198
`W0 99;"45128
`W0 99349059
`W0 99.951620
`W0 99r'51'i66
`W0 00.34317
`W0 03.9002 598
`
`10il989
`131990
`| [#1990
`1:“ l 978
`5i1985
`'i.’ 1981
`1231986
`8:198?
`831984
`1’1985
`5:"[986
`@1986
`12il988
`1231988
`11989
`l.-"l990
`10.-'1991
`| 131994
`6:199?
`12il99?
`8il999
`9il999
`931999
`10il999
`[0’ I999
`6:"2000
`l.-"2[]03
`
`OTHER PUBLICATIONS
`
`Gase et al._. “Functional significance of NH2— and COOH—
`terminal regions of staphylokinase in plasminogen activa—
`tion." Thrombosis and Haeinosrasis, 76(5):?55-760. 1996.
`Giacomini et a]., “Modulation by recombinant DNA
`leukocyte (alpha) and fibroblast (beta) interferons of the
`expression and shedding of HLA— and tumor—associated
`antigens
`by
`human melanoma
`cells,”
`J.
`Inmnmoi._.
`133(3):1649-1655. 1984.
`Gillies et al.. “Antigen binding and biological activities of
`engineered mutant chimeric antibodies with human tumor
`specificities.”Hnm. Antibodies [{i’bridomas._. 1:47—54. 1990.
`Gould et al.. “Phase I study of an anti-breast cancer
`immunotoxin by continuous infusion: report of a targeted
`toxic effect not predicted by animal studies." J. Nari. Cancer
`inst. 81:775—781. 1989.
`Green et al.. “Monoclonal antibody therapy for solid
`tumors.“ Cancer Yrear Rem. 26:269-286, 2000.
`Greiner et al.. “Differential ellects ol‘ recombinant human
`leukocyte interferons on cell surface antigen expression.”
`Cancer Res. 46:4984—4990. 1986.
`Greiner et al., “Enhanced expression of surface tumor—
`associatod antigens on human breast and colon tumor cells
`after recombinant human leukocyte alpha-interferon treat-
`ment." Cancer Res. 44:3208—3214, 1984.
`Haddad et al.. “Structural organization ofthe hCTLA—l gene
`encoding human granzyme 13." Gene, 87(2):265-271, 1990.
`Hamburger and Salmon, “Primary bioassay of human tumor
`stem cells.“ Science, 197:461—463, 1977.
`Hann et al.. “Building ‘validated‘ mouse models of human
`cancer." Curr: Opin. Ceii Biol. 13:778—784. 2001.
`Ilanson c1 al., “A cluster of hematopoietic serine protease
`genes is l'otmd on the same clmimosomal band as the human
`onto T—cell receptor locus.” Proc. Nari. Acad. Sci, USA.
`87:960—963. 1990.
`Harlow et al.. Antibodies: A iaboratorj-‘Manuei. Cold Spring
`Harbor Press, pp. 72-77. 92-97, 128-135. and 141-157,
`1988.
`
`Ilarper et' al.1 “Proximity of the (“1‘1 .A-l serine esterase and
`Tcr alpha loci
`in mouse and man," Inmmnogeneiics,
`28(6):439~444. 1988.
`Henkart. “Mechanism of Lymphocyte—mediated Cytotoxic—
`ity,“ Ann. Rev. imimmoi., 3:31-58, 1985.
`IIertler et al.. “A phase [ study of TlOl-ricin A chain
`immlmotoxin in refractory chronic lymphocytic leukemia.“
`J. Bioi. Response Mod. 7:97—113. 1987.
`Hoogenboom et al., “Targeting of tumor necrosis factor to
`tumor cells: secretion by myeloma cells of a genetically
`engineered antibody-tumor necrosis factor hybrid mol-
`ecule," Biochim Biophys .‘lC‘Ifl.. 1096:345-354. 1991.
`Iluston et al.. “Single-chain inununotcchnology of IN ana-
`logues and fusion proteins." in intmanofeoimoiogv. Gosling
`and Reen (eds), p. 47—60. 1993.
`Imai et a1. “[Current status of monoclonal antibodies to
`luunan melanoma and its application].” Gm? 7b Kagaim
`Ryoimu 10:852-860. 1983 (abstract in English).
`Imai et al.. “Diflerential efl'ect of interferon on the expres—
`sion of tumor—associated antigens and histocompatibility
`antigens on human melanoma cells: relationship to suscep-
`tibility to immlme lysis mediated by monoclonal antibod-
`ies."J. inmmnoi.. 127(2):505-509. 1981.
`Johnson, “Review: Noncaspase proteases in apoptosis,"
`Leukemia. 14:1695—1703. 2000.
`Juhl et a]., “New approaches in gastric cancer research: I.
`Monoclonal
`antibodies
`in
`diagnosis
`and
`therapy.“
`Hepatogasfroenfemi. 36:27—32. 1989.
`Julius et al._. “Induction of resting B cells to DNA synthesis
`by soluble monoclonal
`anti—mununoglobulin,” Em:
`J.
`Inmmnoi.. 14:753-757, 1984.
`Kagawa et al.. “A binary adenoviral vector system for
`expressing high levels of the proapoptotic gene bax.” Gene
`Heragv. 7:75—79, 2000.
`Kagawa et al., “Antitumor Efl'ect of Adenovirus—mediated
`Bax Gene Transfer on p53-sensitive and p53-resistant Can-
`cer lines,“ Cancer Research. 60: 1157-1 161. 2000.
`Kam et al.. “Review: Granzymes {lymphocyte serine
`proteases): characterization with natural and synthetic sub—
`strates and inhibitors,“ Biocizimica er Biophysica Acra,
`1477:307-323. 2000.
`Kaneta et al.. “tilled of gelonin immunoconjugate with
`monoclonal
`antibody
`MSN—l
`to
`endometrial
`adenocarcinoma on antigen—producing tumor cells in vivo,"
`{on J. Cancer Res, 89(5):583-588, 1998.
`Kimmel et al.1 “In vitro drug sensitivity testing in human
`gliomas,“ J. Near-03mg. 66:161—171. 1987.
`Kirlmrood et al.. “Scintigraphic detection ofmetastatic mela—
`noma using indium llliDTI’A conjugated anti—gp240 anti—
`body (mm-018).“J. (11in. ()ncoi..511247-1255. 1987.
`Klein ct al., “Genomic organization and chromosomal
`assignment for a serine protease gene (CSPB) expressed by
`human cytotoxic lymphocytes." Genomics. 5(1):110—117.
`1989.
`
`Kovarik et' al.1 “Biochemical and histochemical character-
`istic of target antigen detected by monoclonal antibody
`HBCa—12 against a membrane component of human mam—
`mary carcinoma cell
`line.” Neopiasma. 31(6):625—630.
`1984.
`
`Kuli: et al.. “Differential reactivity of a novel monoclonal
`antibody (DF3) with human malignant vs. benign breast
`tumors." Iii-'brfdoma. 3(3):223—232_. 1984.
`Kung et al.. “A mouse IgM allotypic determinant Ugh—6.5)
`recognized by a monoclonal rat antibody.” J.
`inmmnoi.
`1271873-876. 1981.
`
`IMMUNOGEN 2075. pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`IMMUNOGEN 2075, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`US 7,083,957 B2
`
`Page 3
`
`J.
`
`lamben et al.. “Immunotoxins containing single chain ribo-
`some—inactivating proteins,” in Inmmnotoxins. Frankel ed._.
`p. 175—209. 1988.
`Lambert et al.. “Purified immunotoxins that are reactive with
`human lymphoid cells. Monoclonal antibodies conjugated to
`the
`ribosome-inactivating
`proteins
`gelonin
`and
`the
`pokeweed
`antiviral
`proteins.“
`Biol.
`(37mm.
`260(22):]2035—12041. 1985.
`Lazar et a1._. “Transforming growth factor alpha: mutation of
`aspartic acid 47 and 1eucine 48 results in difl’erent biolog'cal
`activities." Mol. Cell. Biol.. 8:1247-1252. 1988.
`I.eibovit'x et al.. “A hypo-osmotic medium to disaggregate
`tumor cell clumps into viable and clonogenic single cells for
`the human tumor stem cell clonogenic assay,” 1m. J. Cell
`Cloning. 1:478—485. 1983.
`Lewis and Crowe, “Generation of humanized monoclonal
`antibodies by ‘best’ fit framework selection and recombinant
`polymerase chain reaction.” Year
`linninnol.. 7:110-118.
`1993.
`Lin et al.. “Chromosomal localization of two human serine
`protease genes to region 14qll.2--
`(.112 by in situ hybrid-
`ization." (.j-‘rogenel Cell Genet. 53(2-3):169-171, 1990.
`[.ubin et al.. “Analysis ofthe human factor V111 A2 inhibitor
`epitope by alanine scanning mutagenesis.” J. Biol. Chem,
`272(48130191—30195. 1997.
`Miescher—(‘iranger et al.1 “Biological activities of human
`recombinant interferon alphalbeta targeted by anti-Epstein-
`Barr virus monoclonal antibodies.” FEBS Lem. 179:29—33.
`1985.
`
`Mihich. “Future perspectives for biological response inedi—
`fiers: a viewpoint." Sen: Oneal. 13:234-254, 1986.
`Montanaro et al.. “A metalloproteinase associated with
`gelonin. a ribosome inactivating protein.” Ital. J. Bioehein..
`p. 1—10. 1984.
`Moola et
`al.. “Erwinia chrysanthemi L—asparaginase:
`epitope mapping and production of antigenically modified
`enzymes,” Bioelrem .1. 302( Pt 3):921-7, 1994.
`Motyka et al.. “Mannose 6—phosphatelinsulin—like growth
`factor II receptor is a death receptor for granzyme B during
`cytotoxic T cell-induced apoptosis." Cell. 103(3):49l-500.
`20(10.
`
`Mujoo et al.. “Pharmacology and therapeutic studies with
`ZME—gelonin immunotoxin." Proc. Am Assoc. Cancer Res.
`32:266. #1580. 1991.
`Murray et al.1 “Clinical parameters related to optilnal tumor
`localization of indium-1 1 l-labeled mouse antimelanoma
`monoclonal antibody ZME—018”J. Nuclear Med. 28:25—33.
`1987.
`
`Murray et al.. “Difl'erential in vitro effects of alpha recom—
`binant interferon and gamma recombinant interferon on the
`expression of melanoma-associated antigens and 240 Kd on
`melanoma cell line T5294.” AACR. 27:313. 1986.
`Murray et al.. “Difl'erential in vitro efl'ects of recombinant
`alpha-interferon and recombinant gamma-interferon alone
`or ill combination on the expression of melanoma-associated
`surface antigens,“ J. Biol. Response Mody‘iers. 7:152-161.
`1988.
`
`Neville et al.. “Monoclonal antibody—ricin or ricin .A chain
`hybrids: kinetic analysis of cell killing for tumor therapy,”
`lmninnol. Reta. 62:75-91. 1982.
`Nolan et al.. “Cloning and expression of a gene encoding
`gelonjn, a ribosome—inactivating protein from Gelonium
`multiflorum." Gene. 134:223—227. 1993.
`Nuti et al.. “A lnonoclonal antibody (1372.3) defines paltems
`of distribution ofa novel tumor-associated antigen ill human
`
`.1. Cancer,
`
`mammary carcinoma cell populations." int.
`29(5):539—546_. 1982.
`Ozawa et al.. “Selective killing of squamous carcinoma cells
`by an immunotoxin that recognizes the EGF receptor." lnr.
`J. Cancer. 431152-157, 1989.
`Pagliaro et al.. “IIumanizcd M195 monoclonal antibody
`conjugated
`to
`recombinant
`gelonin:
`an
`anti-CD33
`immunotoxin with antileukemic activity," Clin. Cancer
`Res. 4(8):]971—1976, 1998.
`Pai and Pastan “Immunotoxin therapy for cancer.” JAMA.
`269:78-81. 1993.
`Pastan et' al.. “Recombinant toxins for cancer treatment.“
`Science, 254:1173-1177. 1991.
`Pearson et a1._. “Enhanced therapeutic eflicacy against an
`ovarian tumor xenograft of immunotoxins used in conjunc—
`tion with recombinant alpha—interteron.” Cancer Res.
`50:6379-6388, 1990.
`Pelham et al.. “interferon-alpha conjugation to human
`osteogenic sarcoma monoclonal antibody 7911736.” Cancer
`liimiimol. lmimrnollrert, 15:210—216. 1983.
`Ramakrishnan and Houston. “Prevention of growth of leu-
`kemia cells in mice by monoclonal antibodies directed
`against Thy 1.1 antigen disulfide linked to two ribosomal
`inhibitors: pokeweed antiviral protein or ricin A chain.”
`Cancer Res" 44(4):l398—404. 1984.
`Raso et al.. “Monoclonal antibody-ricin A chain conjugate
`selectivity cytotoxic for cells bearing the conu'non acute
`lymphoblastic leukemia antigen.” Cancer Res. 42:457—464.
`1982.
`
`Reirnann et al.. “In vivo administration of lymphocyte—
`specific monoclonal antibodies in nonhuman primates. IV.
`Cytotoxic effect of an anti-'1'] l-gelonin innnunotoxiu," J.
`Clin. Invest. 82:129—138. 1988.
`Rissoan et al.. “Subtractive hybridization reveals the expres—
`sion of inmlunoglobulinlike transcript 7. Eph—Bl _. granzyme
`13 and 3 novel transcripts in human plasmacytoid dendiritic
`cells," Blood. 1(10(9):3295-3303, 2002.
`Rosenblum et al.. “A gelonin—containing immunotoxin
`directed against human breast carcinoma,” Moi. Biolher.
`4:122-129. 1992.
`Rosenblum et al.1 “Antibody-mediated delivery of tumor
`necrosis factor (INF-or)? l’roc. Am Cancer Res, 30:410.
`#1522. 1987.
`
`Rosenblum et al.. “Antibody—mediated delivery of tumor
`necrosis factor (TNli-alpha):
`improvement of cytotoxicity
`and reduction of cellular resistance." Cancer Connnan.
`3:21—27, 1991.
`Rosenblum et al.. “Growth inhibitory efl'ects of interferon—
`beta but not interferon—alpha on human glioma cells: corre—
`lation of receptor binding, 2'.5'-oligoadeny1ate synthetase
`and protein kinase activity.“ lnrerferon Res.. 101141-151,
`1990.
`
`Rosenblum et al.. “Monoclonal Antibodies for delivery of
`cytokines,“ Cancer Brill. 46(1 )134-39, 1994.
`Rosenblum et al.. “An antirnelanoma ilnmunotoxin com-
`posed of antibody AMI-018 and the plant toxin gelonin,“ ,
`Proc'. Am. Assoc. Cancer Res. Anna. Meet" 29:427. #1700.
`1988 (Abstract).
`Rosenblum et al.. “Tumor necrosis factor a: multifaceted
`
`peptide hormone,“ Critical Reviews in lmninnolog}-'. pp.
`21—44. 1989.
`Ross et a1._. “Increased toxicity ofdiphtheria toxin for human
`lymphoblastoid cells following covalent linkage to anti—
`(human lymphocyte) globulin or its l"(ab')2 fragment." liar.
`J. Bioebel'n. 104:381-390, 1980.
`
`IMMUNOGEN 2075, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`IMMUNOGEN 2075, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`US 7,083,957 B2
`
`Page 4
`
`Roy et a1., “Anti-MY‘J-blockcd-ricin: an inununotoxin for
`selective targeting of acute myeloid leukemia cells." Blood.
`772404—2412. 1991.
`Salmon and Liu “Effects of granulocyte—macrophage
`colony-stinntlating factor on in vitro growth of human solid
`tumors," J. (71in. ()nco1., 7:]346-1350. 1989.
`Salmon et a1., “livalualion of an automated image analysis
`system for counting human tumor colonies.” Internet. J.
`Cell Cloning, 2:142—160, 1984.
`Salmon et al.. “Quantitation of difl'erential sensativity of
`human-tumor stem cells to anticancer drugs,“ New Eng. J.
`Meat, 298:1321-1327, 1978.
`Schienberg et a1., “Monoclonal Antibody M 195:A diagnos-
`tic marker for acute niyelogenous leukemia.” Leukemia.
`3(6):440445. 1989.
`Scholz et al.. “Correlation of drug response in patients and
`in
`the
`clonogenjc
`assay with solid human tumour
`xenogralts." Eur: J. Cancer. 26(8):901-905. 1990.
`Schulz et al., “Monoclonal antibody—directed effector cells
`selectively lyse human melanoma cells in vitro and in vivo."
`Proc. Natl. Acad. Sci. USA. 80:5407-5411, 1983.
`Scott et al.. “An innnunotoxin composed ol‘ a monoclonal
`antitranslerrin receptor antibody linked by a disulfide bond
`to the ribosome—inactivating protein gelonin: potent in vitro
`and in vivo effects against human tumors,” J. Natl. Cancer
`1m, 79211634172, 198?.
`Shoemaker et al.. “Application of a human tumor colony-
`l'orming assay to new drug screening.” Cancer RES"
`452145—2153, 1985.
`Sinw et al.. “Hormonotoxins. Preparation and characteriza—
`tion of ovine luteinizing hormone-gelonirt conjugate," J.
`Biol. Chem" 264(6):3(l89-3095. 1989.
`Sivam et al.. “Immunotoxins to a human melanoma—associ—
`
`ated antigen: comparison of gelonin with ricin and other A
`chain conjugates," Cancer Res" 4731698173. 1987.
`Smyth cl a1., “Granzymes: exogenous proteinases that
`induce target cell apoplosis.” Immunologic Today. 16(4):202-
`206. 1995.
`l 26—kilodalton
`“Membrane
`al._.
`et
`Soule
`phosphoglywprotein associated with human carcinomas
`identified by a hybridoma antibody to mammary carcinoma
`cells.“ Proc. Natl. Acad. Sci. USA. 80:1332-1336, 1983.
`Spitler et al.. “Inimunotoxin therapy of malignant mela—
`noma,” Med Oncol' Tumor Pharmacorben. 3: 147—152. 1986.
`Spiller eta1.. “Therapy of patients with malignant melanoma
`using a monoclonal antimelanoma antibody-ricin A chain
`immunotoxin.” Cancer Res“ 47:1717—1723, 1987.
`Spitler et al.. “Therapy of metastatic malignant melanoma
`using XomaZyme Me]. a murine monoclonal anti—melanoma
`ricin Achain immunotoxin.“ Nac. Med. And 317015., 16:625-
`627. 1989.
`Tai et al., “In Vivo Cytotoxicity of Ovarian Cancer Cells
`through Tumor—selective Expression of the BAX Gene.”
`Cancer Rest, 59:2121-2126, 1999.
`Tao et al.. “Studies of aglycosylatcd chimeric mouse-human
`lgG. Role ol‘ carbohydrate in the structure and effector
`functions mediated by the human lgG constant region.” J.
`lnnnnnol.. 143:2595—2601. 1989.
`'l'eddcr et al.. “l-‘lpstein Barr virus binding induces intcmal-
`ixation ot‘ the (73d receptor: a novel immunotoxin delivery
`system," J. Immanol. 137(4):l387—1391. 1986.
`Thorpe et al.. “An immunotoxin composed of monoclonal
`anti—thy 1.1 antibody and a ribosome—inactivating protein
`from saporiaria oddicinalis: potent antiltunor efictts ill vitro
`and in vivo.“J. Natl. Cancer inst, 75(1):lSl-159, 1985.
`
`Thorpe et al., “(Tylotoxicity acquired by conjugation of an
`anti—Thy 1.1 monoclonal antibody and the ribosome—inacti—
`vating protein. gelonjn.” Em: J. Biochem. 116:447—454.
`1981.
`
`Thorpe et a1., “Monoclonal antibodies: clinical and regula-
`tory issues.“ Trends Biotechnol. 11:40-42, 1993.
`Till et al., “An assay that predicts the ability of monoclonal
`antibodies
`to
`form potent
`ricin A chain—containing
`inmtunotoxins." Cancer Res. 48:1119—1123, 1988.
`Trowbridge et al.. “Anti—transferrin receptor monoclonal
`antibody and toxin-antibody conjugates alloct growth of
`human tumour cells," Nature. 2941171473. 1981.
`Vitetta eta1.. “Neoplastic B cells as targets lorantibody-ricin
`A chain imniunotoxins.” .. 62:15—183. 1982.
`Vitetta et al.. “Redesigning nature’s poisons to create anti—
`tumor reagents.” Science, 238:1098—1104, 1987.
`V’oge] et al.. “In vivo studies with covalent conjugates of
`cobra venom l‘actor and monoclonal antibodies to human
`tumors." Hematology and Blood Transfirsion. 29:514—517.
`1989.
`
`Von Hoff. “Human tumor cloning assays: applications in
`clinical oncology and new antinooplastic agent develop-
`ment,“ Cancer and Metastasis Reviews, 71357-37], 1988.
`Waldenamn. “Mullichain interleukin-2 receptor: a target for
`innnunotherapy in lymphoma.” J. Natl. Cancer Inst. 81:914—
`923. 1989.
`
`Waldmann at al.. “Monoclonal antibodies in diagnosis and
`therapy.“ Science. 252:1657-1662, 1991.
`White et a1., “Two monoclonal antibodies selective for
`human mammary carcinoma“ Cancer Res. 45:1337—1343.
`1985.
`
`Wilson et a], “Distribution and molecular characterization of
`a cell—surface and a cytoplasmic antigen detectable in human
`melanoma cells with monoclOnal antibodies.“ Int. J. Cancer,
`28:293-300. 1981.
`and
`ot-momorcharin
`“'l‘ricliosattthin.
`Yeung
`et
`al..
`[i—momorcharin: identity of aborit'acient and ribosome—inac—
`tivating proteins," Int. J. Pept. Protein Rest, 31(3):265—8,
`1988.
`
`Yokota et a1., “Synergistic potentiation of in vivo antitumor
`activity of anti-human T—leukemia immunotoxins by recom-
`binant alpha—mterferon and daunorubicin." Cancer Rest,
`50:32—37, 1990.
`Young. “Cell—Mediated Killing: A common Mechanism?“
`Cell. 46:641-642. 1986.
`Yang el a1., “In vitro chemoscnsitivity testing and its clinical
`application in human gliomas." Nearesm'g. Rem, 12:197-
`203. 1989.
`
`Zuckerman et al.. “Preparation and biological activity of
`recombinant leukocyte interferon A [rIFN alpha A] conju—
`gated to an antimelanoma murine monoclonal antibody
`[IMF-018]." l’roc. Amer. Assoc. Cancer Rest. 28:384. 1987.
`Aboud-Pirak et al.. “Cytotoxic activity of daunortlbicin or
`vindesine conjugated to a monoclonal antibody on cultured
`MC F—7 breast carcinoma cells.” Bfoclzem. Phat-mace!”
`38:641—648, 1989.
`Adants ct a1., “The Bel-2 Protein liamily: Arbiters of Cell
`Survival." Science, 281:1322-1326. 1998.
`Aggarwal and Kohr, “Human tumor necrosis factor.” Meth—
`ods in Enzvriiologv. 116:448456. 1986.
`Alkan et al.. “Antiviral and antiproliferative effects of
`interferons delivered via monoclonal antibodies.“ J.
`Inter—
`jeron Res., 4(3):355-363, 1984.
`
`IMMUNOGEN 2075, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`IMMUNOGEN 2075, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`US 7,083,957 B2
`
`Page 5
`
`Alley et a1., “Feasibility of drug screening with panels of
`human tumor cell lines using a microculture tetrazolium
`assay.” Cancer Res. 48:589—601. 1988.
`Aqeilan et al.. “Interleukin 2—Bax: a novel prototype of
`human chimeric proteins for targeted therapy,” l“l:‘BS Ler—
`iers, 457:271-276, 1999.
`Anion et al.. “Monoclonal antibodies for immunotargeting
`of drugs in cancer therapy." Monoclonal Antibodies and
`Cancer Therapy, Alan R. Liss, Inc. pp. 243—256, 1985.
`Atkinson et al.. “Conjugation of folate via gelonin carbo—
`hydrate residues retains ribosomal-activating properties of
`the toxin and permits targeting to lolate receptor positive
`cells.“ Biochem Molee. Biol, 276(30):27930-27935, 2001.
`Barbieri and Stirpe. “Ribosome—inactivating proteins from
`plants: Properties and possible uses.” Cam-er Surveys.
`l(3):489—520.
`Batra at al., “Antitumor activity in mice o f an inununotoxin
`made with anti-transferrin receptor and a recombinant form
`of Pseudomonas exotoxiu." Proc. Natl. Acad. Sci. 86:8545—
`8549. 1989.
`Batra at al._. “Single—chain immunotoxins directed at the
`htnnan
`transferrin
`receptor
`containing
`Pseudomonas
`exoloxin A or diphtheria toxin: anti-'1‘FR[Fv)—Pli40 and
`|)1‘388-an1i-’l‘lll{(liv),” Moi.
`(fell. Biol. 112200-2205,
`1991.
`
`Bendig. “Humanization of rodent monoclonal antibodies by
`CDR grafiing," METHODS: A Companion :0 Methods in
`lfnzwnologir, 8:83-93. 1995.
`Bjorn et al.. “livaluation of monoclonal antibodies for the
`development of breast cancer inm‘ltlnotoxins.“ Cancer Rein.
`45:1214—1221, 1985.
`to
`agents
`cytotoxic
`of
`Blair
`et
`al._.
`“Linkage
`inlmunoglobulins.” J.
`Inmmnol. Meilzods. 59:129—143.
`1983.
`
`Blakey et a1., “Antibody toxin conjugates: a perspective,”
`Monoclonal Antibody linemen. Waldrnann (ed). 45:50-90.
`1988.
`
`Blink et al._. “Curtin Conference: Perform—dependent nuclear
`targeting of granzymes: A central role in the nuclear events
`of grannle-exocytosis-mediated apoptosis'h“ lmnninologt’
`and Cell Biology, 771206-215, 1999.
`Bolognesi et al.. “In vitro anti—tumour activity of anti—CD80
`and anti—CD86 immunotoxins containing type 1 ribosome—
`inactivating proteins.“ 3}: J. Haematol, 110(2):351-361.
`2000.
`
`Bradford et a1., “A rapid and sensitive method for the
`quantitation ofmicrogram quantities of protein utilizing the
`principle of protein—dye binding”.
`aly. Biochem._. 72:248—
`252. 1976.
`
`Brunet et al., “The inducibile cytotoxic '[Llymphocyte-asso-
`ciated gene transcript CTLA—l sequence and gene localiza—
`tion to mouse chromosome 14.” Nature. 322(6076):268—
`271, 1986.
`[Sumol et a1., “Biosynthetic studies of proteoglycans in
`human melanoma cells with a monoclonal antibody to a core
`glycoprotein of chondroitin sulfate proteoglycans.” .1 Biol.
`Chem. 259:12733—12741. 1984.
`Chan ct a1., “Comparison of gallium-6'? versus indium-111
`monoclonal antibody (96.5, ZMli-OIS)
`in detection of
`human melanoma in athymic mice,"J. Neel. Meal. 28:1441—
`1446. 1987.
`Chaudhary et al.. “A recombinant immunotoxin consisting
`of two antibody variable domains fused to Pseudomonas
`exotoxin," Nature, 339:394-397. 1989.
`
`Collen et a1., “Recombinant staphylokinase variants with
`altered inununoreactivity.“ Circulation. 94:197—206. 1996.
`Cotton et al._. “Somatic mutation and the origin of the
`antibody diversity. Clonal variability of the immunoglobulin
`produced by MOPC 21 cells in culture.“ Em: J. lnnminol.,
`3:135-140, 1973.
`Crosby et al._. “A complex of serine protease gene expressed
`preferentially in cytotoxic T—lymphyocy‘tes is closely linked
`to the Tcell receptor alpha— and delta—chain genes on mouse
`chromosome 14.” Geaomics. 6(2):252—259. 1990.
`l)a111 et al.. “Isolation of a cl)NA clone encoding a novel
`form of granzyme 13 from human NK cells and mapping to
`chromosome 14,“ Hum. Genet, 84(5):465-470, 1990.
`DeLand et at. “A perspective of monoclonal antibodies: past.
`present. and future." Seminars in Nae. Meal. l9(3):158—165.
`Denner, “Another anniversary for the war on cancer.” Biol
`iechnologl’. 12: 320. I994.
`Dillman. “Monoclonal antibodies for treating cancer.” Ann.
`Iniern. Med. 111:592—603. 1989.
`the role of
`Dumontet. “[Inununotherapy and cancer:
`monoclonal antibodies].” J. Chir.
`(Paris). 126:682—686.
`1989.
`
`lingert et a1., “Resistance ofmyeloid leukaemia cell lines to
`ricin A-chain inununotoxins,“ Leak. Res, 15:1079-1086,
`199].
`
`Falasca et al.. “Properties of the ribosome—inactivating pro—
`teins
`gelonin. Momordica
`charantia
`inhibitor.
`and
`dianthins," Bioelzem. J., 207:505-509, 1982.
`l’iers et' a1. “Tumor necrosis factor: a potential anti tumor
`agent." J. Interferon Rein. 7:627—634. 1987.
`Flannery et al._. “lmmunomodulation: NK cells activated by
`interferon—coniugated monoclonal antibody against human
`osteosarcoma" Eur: J. Cancer Clin. Oncol. 20:791—798.
`1984.
`Frankel et a1., “Prospects for immunotoxin therapy in can-
`cer." Ann. Rem Meal. 37:125-142. 1986.
`Freshney, “Culture of animal cells. a manual of basic tech—
`nique,” Alan R. Liss. Inc, 1983.
`Friedman et al.. “BR96 sliv-Pl-i40, a potent single-chain
`inu'mu‘rotoxin that selectively kills carcinoma cells," Cancer
`Res.. 53:334-339, 1993.
`Frontiera et al.. “Sequential use of indium—111 labeled
`monoclonal antibodies 96.5 and ZME—Ol 8 does not increase
`detection sensitivity for metastatic melanoma,“ Clin. Noel,
`Meal. 14:357-366. 1989.
`Gallego et a1., “Preparation offour daunomycin—monoclonal
`antibody 7911736 conjugates with anti—tumour activity." lni.
`J. Cancer, 33:737—744, 1984.
`Alfthan et a1., “Properties of single-chain antibody contain-
`ing dilfereut linker peptides,” Protein Engineering; 8:725-
`731. 1995.
`Berkower. “The promise and pitfalls of monoclonal anti—
`body therapeutics.“ Current Opinion in Hioreelanologl’,
`7:622-628. 1996.
`
`Bird et a1., “Single-chain antigen-binding proteins.” Sci—
`ence;242:423-426. 1988.
`GenBank Accession No. L122A-3.
`Kiln and Weaver, “Construction 0 fa recombinant expression
`plasmid encoding a staphylococcal protein A-ricin A fusion
`protein." Gene: 68:315—321. 1988.
`Kipriyanov et a1., “Recombinant single—chain Fv fragments
`carrying c—terminal cysteine residues: production of bivalent
`and biotinylated miniantibodies.” Molecular linmanologl’,
`31:1047—1058. 1994.
`
`IMMUNOGEN 2075, pg. 5
`Phigenix v. Immunogen
`IPR2014-00676
`
`IMMUNOGEN 2075, pg. 5
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`US 7,083,957 B2
`Page 6
`
`Koizumi et a1., “Immunoscintigraphy and pharmacokinetics
`of indiutn—lll—labeled ZME018 monoclonal antibody in
`patients with malignant melanoma," Japanese J of Cancer
`Res. 79:973—981. 1988.
`
`Kudlicki et al.. “Elongation and folding of nascent ricin
`chains as peptidy-rRNA on ribosomes: the elfect of amino
`acid deletions on these processes.“ J. Moi. Biol. 1252:203-
`212. 19.95.
`Kurucz et al.. “A bacterial expressed single-chain 1"v con-
`struct from the 2B4 Tcell receptor." Pros Nari Acad Sci
`USA: 90: 3830—3834. 1993.
`
`Levy et al.. “Retroviral transfer and expression ot'a human—
`ized. red-shifted green lluorescent protein gene into human
`tumor cells.“ Nat. Biotechnol. 14:610-614. 1996.
`
`Macey et a1., “Uptake of Indium-lll-labeled monoclonal
`antibody 219113-018 as a function of tumor size in a patient
`with melanoma." Am J ofPhysiologic InmgingS: 1—6. 1988.
`Mazurier et al.. “Rapid analysis and efficient selection of
`human transduced primitive hematopoietic cells using the
`humanized 8651 green lluorescent protein." Gene Wren.
`51556-562. 1998.
`McCartney et al.. “Engineering disulfide—linked singl-chain
`Fv dimers [{st')2] with improved solution and targeting
`properties: anti-digoxin 26-10 [sliv'JZ and anti-c-erbB-Z
`74lIi8 (sI’v')2 tnade by protein folding and bonded through
`C-terminal cyst'einyl peptides.“ Protein Engineering; 8:301-
`314. 1994.
`Morris and Wool. “Determination by systematic deletion of
`the amino acids essential for catlysis by riein A chain.” i’roc.
`Nari. Acad. Sci. USA. 89:4869-4873. 1992.
`Mujoo et al.. “Pharmacokinetics. tissue distribution. and in
`vivo antitumor efl'ects of the antimelanoma innnttnotoxin
`
`Inimttnoiogv.
`
`ZME—gelonin." Cancer
`40:339-345. 1995.
`Mttldoon et al., “’l‘racking and quantitation of retroviral-
`mediated transfer using a completely humanized. red—shifted
`green fluorescent protein gene,” Bioiechniqites. 22: 1 62—167.
`1997.
`
`Iinnmnoiberapv;
`
`Munislikin and Wool. “Systematic deletion analysis of riein
`A-chain litnclion.“ J Bioi. Chem" 270:30581-30587. 1995.
`Nechushtan et al.. “Conformation of the Bax C—termintts
`regulates subcellular location and cell death.” EMBO Jour—
`nai. 18:2330-2341. 1999.
`O’Boyle et al.. “Potentialion of atttiproliferatiVe elfects of
`monoclonal antibody lYtn-l and itrunttnoconjugate Lym-l -
`gelonin on human Burkitt’s lymphoma cells with y—inter—
`feron
`and
`tumor
`necrosis
`factor,"
`Journal
`of
`hnnmnorberapt’: 18:221-230. 1995.
`0’1 [are et al.. “Cytotoxicily of a recombinant ricin-A-chain
`fusion protein containg a proteolytically—cleavable spacer
`sequence.” FEBS Lett,: 273:200-204. 1990.
`Owens and Young, ”The genetic engineering of monoclonal
`antibodies.“ .Iortrnai of hnnmnoiogicai Methods: 168:149-
`165, 1994.